Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

ABSTRACT:

Background

This study describes a repeated measures prediction index to identify patients at high risk of ≥grade 2 hand-foot skin reaction (HFSR) before each week of sorafenib therapy.

Methods

Data from 451 patients who received a sorafenib (400 mg bid) as part of a clinical trial were reviewed (Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134). Generalized estimating equations were used to develop the final risk model. A risk-scoring algorithm (range 0-58) was then derived from the final model coefficients. External validation was then carried out on a new sample of 1145 patients who received sorafenib under an expanded access program.

Results

Pretreatment white blood cell count, female gend

SUBMITTER: Dranitsaris G 

PROVIDER: S-EPMC3403729 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature